LGND: Thank you for your review. LGND is a long term holding of mine--purchased shares many years ago @ $6.30. One of the 1st companies I visited in La Jolla, along with AMLN and VICL, in mid-late '90s. AMLN did even better with take-over by BMY, cannot say much for VICL so far.
LGND..$17.49.. DD post with slides. PDUFA date with priority review of Nov 30th. A lot of potential here with Promacta.
PDUFA date upcoming on Nov 30th. http://bit.ly/Rfo1Qy . This is priority review so I am expecting an approval the first week of November. This stock has 19.9m shares o/s and only 14.6m in the float. Should be a solid catalyst play over the next month.
-Cantor believes that two data releases and the PDUFA for Ligand's HCV treatment, Promacta, should drive the stock in coming months. The firm is optimistic about the approval of Promacta in HCV and maintains a $22 target and Buy rating on the stock http://yhoo.it/R97UAB
Market Data 
Markets 
AI
